SCHEMBL4843914

SCHEMBL4843914

Cc1ccc(-c2nc3cc(Br)cnc3[nH]2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.57
CDK5 Q00535 2/20 0.57
ABL1 P00519 1/20 0.57
RET P07949 1/20 0.57
CDK7 P50613 1/20 0.57
PRKAA1 Q13131 1/20 0.57
AURKB Q96GD4 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 2/20 0.52
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
AURKA O14965 1/20 0.44
NPBWR1 P48145 2/20 0.43
TNKS O95271 1/20 0.42
PARP1 P09874 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
CCNB2 O95067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607851 0.85 ALDH1A1 (0.47) KDRCDK5ABL1RETCDK7
SCHEMBL4843784 0.85 MMP2 (0.56) KDRCDK5ABL1RETCDK7
SCHEMBL4839487 0.85 TBK1 (0.45) KDRCDK5ABL1RETCDK7
SCHEMBL9692091 0.85 NPC1 (0.47) KDRCDK5ABL1RETCDK7
SCHEMBL13607760 0.84 PTGES (0.51) KDRCDK5AURKBCLK4SMN1; SMN2
SCHEMBL13607823 0.84 PTGES (0.56) KDRCDK5ABL1RETCDK7
SCHEMBL4841493 0.84 NPC1 (0.50) CDK5AURKBSMN1; SMN2ALDH1A1MAPT
SCHEMBL4840403 0.84 AURKA (0.40) KDRCDK5ABL1RETCDK7
SCHEMBL985911 0.82 CDK5 (0.50) KDRCDK5ABL1RETCDK7
SCHEMBL24074361 0.81 TRPV1 (0.51) NPBWR1TNKSTNKS2CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
EP-1539759-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016611-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 KDR 2160/4885CDK5 283/4885ABL1 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.